Pre-Clinical Data Demonstrates Promising Potential of MannKind Corporation's IRE1aInhibitor to Treat Multiple Myeloma

VALENCIA, Calif.--(BUSINESS WIRE)--Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1a-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma. The pre-clinical study, conducted by researchers at Dana-Farber Cancer Institute in collaboration with MannKind Corporation (Nasdaq: MNKD), confirm that blocking the XBP1 arm of the unfolded protein response with MannKind's novel, first-in-class IRE1a RNase domain inhibitor, MKC-3946, alone or in combination with bortezomib or 17AAG, inhibited growth in multiple myeloma cells, while leaving normal cells intact.